Appraising the European randomized study of screening for prostate cancer: what do the results mean?

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2015,（2）
• 页码范围: 221-222
• 页数: 2页
• 语种: 中文
• DOI: 10.4103/1008-682X.142131

摘要

The value of screening for prostate cancer has been a contentious issue within the medical literature for several decades.At the crux of the matter lies a judgment call of whether the potential benefits of screening,a reduction in prostate cancer and all-cause mortality,outweigh the limitations,overdiagnosisand overtreatment.The study by Schr(o)der et al.reports 9,11 and 13-year follow-up data on men participating in the European randomized study of screening for prostate cancer (ERSPC).While the authors report a significant reduction in prostate cancer mortality,they conclude that potential harms associated with screening currently circumvent any recommendation for a population-based approach to screening for prostate cancer.